Selection of Candida glabrata strains with reduced susceptibility to azoles in four liver transplant patients with invasive candidiasis

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 16, Issue 4, 1997, Pages 314-318

  Fortun J ^a   Lopez San Roman A ^a   Velasco, J J ^a   Sanchez Sousa A ^a   De Vicente, E ^a   Nuno J ^a   Quereda, C ^a   Barcena R ^a   Monge, G ^a   Candela, A ^a   Honrubia, A ^a   Guerrero, A ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; ITRACONAZOLE; PYRROLE DERIVATIVE;

ADULT; ARTICLE; CANDIDA GLABRATA; CANDIDIASIS; CASE REPORT; CAUSE OF DEATH; CHOLANGITIS; DRUG RESISTANCE; FUNGEMIA; HUMAN; INTESTINE PREPARATION; LIVER ABSCESS; LIVER TRANSPLANTATION; MALE; MINIMUM INHIBITORY CONCENTRATION; NEUTROPENIA; PRIORITY JOURNAL;

EID: 8244225815     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01695638     Document Type: Article

References (29)

1. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, Shadduck RK, Shea TC, Stiff P, Friedman DJ, Powderly WG, Silber JG, Horowitz H, Lichtin A, Wolff SN, Mangan KF, Silver SM, Weisdorf D, Ho WG, Gilbert G, Buell D: A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. New England Journal of Medicine 1992, 326: 845-851.
2. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R: Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. New England Journal of Medicine 1991, 325: 1274-1277.
3. Winston DJ, Chandrasekar PH, Lazarus HM, Goodman JL, Silber JL, Horowitz H, Shadduck RK, Rosenfeld CS, Ho WG, Islam MZ, Buell DN: Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Annals of Internal Medicine 1993, 118: 495-503.
4. Chandrasekar PH, Gatny CM: The effect of fluconazole prophylaxis on fungal colonization in neutropenic cancer patients. Journal of Antimicrobial Chemotherapy 1994, 33: 309-318.
5. Borg von Zepelin M, Eiffert H, Kann M, Ruchel R: Changes in the spectrum of fungal isolates: results from clinical specimens gathered in 1987/88 compared with those in 1991/92 in the University Hospital Göttingen, Germany. Mycoses 1993, 36: 247-253.
6. Wingard JR, Merz WG, Rinaldi MG, Miller CB, Karp JE, Saral R: Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrobial Agents and Chemotherapy 1993, 37: 1847-1849.
7. Persons DA, Laughlin M, Tanner D, Perfect J, Gockerman JP, Hathorn JW: Fluconazole and Candida krusei fungemia. New England Journal of Medicine 1991, 325: 1315.
8. McIlroy MA: Failure of fluconazole to suppress fungemia in a patient with fever, neutropenia and typhlitis. Journal of Infectious Diseases 1991, 163: 420-421.
9. Paya CV: Fungal infections in solid-organ transplantation. Clinical Infectious Diseases 1993, 16: 677-688.
10. Meunier F, Aoun M, Gerard M: Therapy for oropharyngeal candidiasis in the immunocompromised host. A randomized double-blind study of fluconazole vs. ketoconazole. Reviews of Infectious Diseases 1990, 12, Supplement 3: 364-368.
11. He X, Tiballi RN, Zarins LT, Bradley SF, Sangeorzan JA, Kauffman CA: Azole resistance in oropharyngeal Candida albicans strains isolated from patients infected with human immunodeficiency virus. Antimicrobial Agents and Chemotherapy 1994, 38: 2495-2497.
12. Ruhnke M, Eigler A, Tonnagen I, Geiseler B, Engelmann E, Trautmann M: Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. Journal of Clinical Microbiology 1994, 32: 2092-2098.
13. White DJ, Johnson EM, Warnock DWTI: Management of persistent vulvo vaginal candidosis due to azole-resistant Candida glabrata. Genitourinary Medicine 1993, 69: 112-114.
14. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing for yeasts. Proposed standard M27-P. NCCLS, Villanova, PA, 1992.
15. Polanco AM, Rodríguez-Tudela JL, Baquero F, Sánchez-Sousa A, Martínez-Suarez J: Improved method of determining the susceptibility of Candida albicans to fluconazole. Journal of Antimicrobial Chemotherapy 1995, 35: 155-159.
16. Rodríguez-Tudela JL, Martínez-Suarez JV: Defining conditions for the microbroth antifungal susceptibility tests: influence of RPMI and RPMI-2% glucose on the selection of endpoint criteria. Journal of Antimicrobial Chemotherapy 1995, 35: 739-749.
17. Odds FC, Vranckx L, Woestenborghs F: Antifungal susceptibility testing of yeasts: evaluation of technical variables for test automation. Antimicrobial Agents and Chemotherapy 1995, 39: 2051-2060.
18. Scheven M: Testing susceptibility of fungi to fluconazole. European Journal of Clinical Microbiology & Infectious Diseases 1993, 12: 393-395.
19. Galgiani JN, Stevens DA: Antimicrobial susceptibility testing of yeasts: a turbidimetric technique independent of inoculum size. Antimicrobial Agents and Chemotherapy 1976, 10: 721-726.
20. Rodríguez-Tudela JL, Berenguer J, Martínez-Suárez V, Sánchez R: Comparison of a spectrophotometric microdilution method with RPMI-2% glucose with the National Committee for Clinical Laboratory Standards reference macrodilution method M27-P for in vivo susceptibility testing of amphotericin B, flucytosine, and fluconazole against Candida albicans. Antimicrobial Agents and Chemotherapy 1996, 40: 1998-2003.
21. Quereda C, Polanco AM, Giner C, Sánchez-Sousa A, Pereira E, Navas E, Fortún J, Guerrero A, Baquero F: Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV-infected patients. European Journal of Clinical Microbiology & Infectious Diseases 1996, 15: 30-37.
22. Dermoumi H: In vitro susceptibility of yeast isolates from the blood to fluconazole and amphotericin B. Chemotherapy 1992, 38: 112-117.
23. Martin E, Parras P, Lozano MC: In vitro susceptibility of 245 yeast isolates to amphotericin B, 5-fluorocytosine, ketoconazole, fluconazole and itraconazole. Chemotherapy 1992, 38: 335-339.
24. Morace G, Manzara S, Dettori G: In vitro susceptibility of 119 yeast isolates to fluconazole, 5-fluorocytosine, amphotericin B and ketoconazole. Chemotherapy 1991, 37: 23-31.
25. Vanden Bossche H, Marichal P, Odds FC, Le Jeune L, Coene MC: Characterization of an azole-resistant Candida glabrata isolate. Antimicrobial Agents and Chemotherapy 1992, 36: 2602-2610.
26. Warnock DW, Burke MJ, Cope EM, Johnson EM, Von Fraunhofer NA, Williams EW: Fluconazole resistance in Candida glabrata. Lancet 1988, ii: 1310.
27. Kerridge D, Nicholas RO: Drug resistance in the opportunistic pathogens Candida albicans and Candida glabrata. Journal of Antimicrobial Chemotherapy 1986, 18, Supplement B: 39-49.
28. Hitchcock CA, Pye GW, Troke PP, Johnson EM, Warnock DW: Fluconazole resistance in Candida glabrata. Antimicrobial Agents and Chemotherapy 1993, 37: 1962-1965.
29. Tollemar J, Holmberg K, Ringden O, Lönnqvist B: Surveillance tests for the diagnosis of invasive fungal infections in bone marrow transplant recipients. Scandinavian Journal of Infectious Diseases 1989, 21: 205-212.